Immune Checkpoint Related Enterocolitis
MCRBSeres TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 update for SER-155 (Live Biotherapeutic) in Immune Checkpoint Related Enterocolitis. The expected timing is based on the latest available company guidance and may change.
Collab w/ MSK. 11/05/25:- IST ongoing; complete enrollment in 2025, clinical readout in early 2026. 02/12/26:- IST fully enrolled; initial SER-155 irEC clinical results, including safety and efficacy, expected early Q2 2026. 03/12/26:- Memorial Sloan Kettering SER-155 irEC IST fully enrolled; 15 patients; Q2 2026 data expected. 05/05/26:- MSK IST in irEC remains fully enrolled; clinical readout of SER-155 data expected in coming weeks (Q2 2026). 06/25/26:- Top-line SER-155 irEC data to be discussed July 8, 2026; MSK IST NCT06801067. 07/08/26:- Topline IST NCT06801067 results: 80% Day 15 response; 33% Day 43 response. Future conference presentation planned. 08/05/26:- IST NCT06801067 data reiterated; safety clean; partners sought for irEC development.
Verification
Confirm timing and program details against the company announcement or filing.